215 related articles for article (PubMed ID: 27742064)
1. Present and future of personalized medicine in CLL.
Montserrat E; Bauman T; Delgado J
Best Pract Res Clin Haematol; 2016 Mar; 29(1):100-110. PubMed ID: 27742064
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
3. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Tam CS; Stilgenbauer S
Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
[TBL] [Abstract][Full Text] [Related]
4. Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
Chin-Yee B; Sadikovic B; Chin-Yee IH
Br J Haematol; 2020 Mar; 188(5):652-660. PubMed ID: 30836431
[TBL] [Abstract][Full Text] [Related]
5. TP53 dysfunction in CLL: Implications for prognosis and treatment.
Te Raa GD; Kater AP
Best Pract Res Clin Haematol; 2016 Mar; 29(1):90-99. PubMed ID: 27742075
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
7. Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.
Turcsanyi P; Kriegova E; Kudelka M; Radvansky M; Kruzova L; Urbanova R; Schneiderova P; Urbankova H; Papajik T
Leuk Res; 2019 Apr; 79():60-68. PubMed ID: 30852300
[TBL] [Abstract][Full Text] [Related]
8. Relevance of TP53 for CLL diagnostics.
Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
[No Abstract] [Full Text] [Related]
9. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
Shindiapina P; Brown JR; Danilov AV
Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
[TBL] [Abstract][Full Text] [Related]
10.
Campo E; Cymbalista F; Ghia P; Jäger U; Pospisilova S; Rosenquist R; Schuh A; Stilgenbauer S
Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727
[TBL] [Abstract][Full Text] [Related]
11. The clinical implications of gene mutations in chronic lymphocytic leukaemia.
Rossi D; Gaidano G
Br J Cancer; 2016 Apr; 114(8):849-54. PubMed ID: 27031852
[TBL] [Abstract][Full Text] [Related]
12. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
14. Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
Do C; Best OG; Thurgood L; Hotinski A; Apostolou S; Mulligan SP; Lower K; Kuss B
Br J Haematol; 2021 May; 193(3):556-560. PubMed ID: 33851417
[TBL] [Abstract][Full Text] [Related]
15. The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.
De Luca G; Cerruti G; Lastraioli S; Conte R; Ibatici A; Di Felice N; Morabito F; Monti P; Fronza G; Matis S; Colombo M; Fabris S; Ciarrocchi A; Neri A; Menichini P; Ferrarini M; Nozza P; Fais F; Cutrona G; Dono M
Hematol Oncol; 2022 Dec; 40(5):962-975. PubMed ID: 35961859
[TBL] [Abstract][Full Text] [Related]
16. What is the best frontline therapy for patients with CLL and 17p deletion?
Badoux XC; Keating MJ; Wierda WG
Curr Hematol Malig Rep; 2011 Mar; 6(1):36-46. PubMed ID: 21153774
[TBL] [Abstract][Full Text] [Related]
17. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC
Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
19. Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia.
Kuss BJ; Tam CS
Intern Med J; 2017 Dec; 47 Suppl 6():5-10. PubMed ID: 29250930
[TBL] [Abstract][Full Text] [Related]
20. Sequencing of chronic lymphocytic leukemia therapies.
Barrientos JC
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):128-136. PubMed ID: 27913471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]